JSPR (Jasper Therapeutics) Cash-to-Debt : 18.84 (As of Mar. 2025)

View and export this data going back to 2021. Start your Free Trial

What is Jasper Therapeutics Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Jasper Therapeutics's cash to debt ratio for the quarter that ended in Mar. 2025 was 18.84.

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, Jasper Therapeutics could pay off its debt using the cash in hand for the quarter that ended in Mar. 2025.

The historical rank and industry rank for Jasper Therapeutics's Cash-to-Debt or its related term are showing as below:

JSPR' s Cash-to-Debt Range Over the Past 10 Years
Min: 10.48 Med: 32.4 Max: 46.41
Current: 18.84

During the past 5 years, Jasper Therapeutics's highest Cash to Debt Ratio was 46.41. The lowest was 10.48. And the median was 32.40.

JSPR's Cash-to-Debt is ranked better than
61.95% of 1469 companies
in the Biotechnology industry
Industry Median: 7.7 vs JSPR: 18.84

Jasper Therapeutics Cash-to-Debt Historical Data

The historical data trend for Jasper Therapeutics's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Jasper Therapeutics Cash-to-Debt Chart

Jasper Therapeutics Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

Dec24

Cash-to-Debt

12.22

29.36

10.48

31.19

39.51

Jasper Therapeutics Quarterly Data
	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Cash-to-Debt	Get a 7-Day Free Trial														46.41	46.12	44.71	39.51	18.84

Competitive Comparison of Jasper Therapeutics's Cash-to-Debt

For the Biotechnology subindustry, Jasper Therapeutics's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Jasper Therapeutics's Cash-to-Debt Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Jasper Therapeutics's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where Jasper Therapeutics's Cash-to-Debt falls into.

Save Embed

;

Save Embed

;

Jasper Therapeutics Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

Jasper Therapeutics's Cash to Debt Ratio for the fiscal year that ended in Dec. 2024 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	71.637	/	(1.089	+	0.724)
	=	39.51

Jasper Therapeutics's Cash to Debt Ratio for the quarter that ended in Mar. 2025 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	48.799	/	(1.835	+	0.755)
	=	18.84

Jasper Therapeutics (NAS:JSPR) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

Jasper Therapeutics Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of Jasper Therapeutics's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Jasper Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Jasper Therapeutics Inc (NAS:JSPR) » Definitions » Cash-to-Debt

Comparable Companies

Traded in Other Exchanges

N/A

Address

2200 Bridge Parkway, Suite 102, Redwood, CA, USA, 94065

Website

https://www.jaspertherapeutics.com

Jasper Therapeutics Inc is a clinical-stage biotechnology company dedicated to enabling cures through hematopoietic stem cell therapy. It is focused on the development and commercialization of safer and more effective conditioning agents and stem cell engineering to allow for expanded use of stem cell transplantation and ex vivo gene therapy.

Executives

Jeetinder Singh Mahal	officer: Chief Operating Officer	C/O JASPER THERAPEUTICS, INC., 2200 BRIDGE PARKWAY, SUITE 102, REDWOOD CITY CA 94065
Velan Capital Master Fund Lp	other: See Footnote 1	1055B POWERS PLACE, ALPHARETTA GA 30009
Carlyle Group Inc.	10 percent owner	C/O THE CARLYLE GROUP, 1001 PENNSYLVANIA AVENUE, N.W., WASHINGTON DC 20004
Thomas G Wiggans	director
William Lis	director	PORTOLA PHARMACEUTICALS, INC., 270 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA 94080
Ron Martell	director, officer: President, CEO & Director	PONIARD PHARMACEUTICALS, INC., 750 BATTERY STREET, SUITE 330, SAN FRANCISCO CA 94111
Herb Cross	officer: Chief Financial Officer	3061 ZANKER RD, SAN JOSE CA 95134
Scott C. Brun	director	C/O CABALETTA BIO, INC., 2929 ARCH STREET, SUITE 600, PHILADELPHIA PA 19104
Edwin Jonathan Tucker	officer: Chief Medical Officer	C/O MIRUM PHARMACEUTICALS, INC., 950 TOWER LANE, SUITE 1050, FOSTER CITY CA 94404
Anna Louise French	director	C/O QIMING U.S. HEALTHCARE, 11100 NE 8TH ST, SUITE 200, BELLEVUE WA 98004
Kurt Von Emster	director, 10 percent owner	601 GATEWAY BOULEVARD, SUITE 350, SAN FRANCISCO CA 94080
Qiming U.s. Healthcare Fund Ii, L.p.	10 percent owner	350 106TH AVENUE NE, 1ST FLOOR, BELLEVUE WA 98004
Llp Abingworth	10 percent owner	38 JERMYN STREET, LONDON X0 SW1Y 6DN
Mark Mcdade	10 percent owner	C/O PROTINE DESIGN LAB, 7442 NORTH MARCER WAY, MERCER ISLAND WA 98040
Qiming U.s. Healthcare Gp Ii, Llc	10 percent owner	11100 NE 8TH ST, SUITE 200, BELLEVUE WA 98004